Brain Metastases (Secondary Brain Tumor)

Brain metastases (secondary brain tumor), which are associated with extremely poor outcomes and seriously diminish patient quality of life, are the most common intracranial neoplasms in adults. The incidence of brain metastasis is increasing, likely due to improved detection of small metastases by MRI and improved management of extracerebral disease by progress of systemic therapy.

Current treatment options for brain metastasis include surgical resection, radiotherapy, and systemic therapies, alone or in combination. The evolution of surgical and radiosurgical techniques over the past several decades has led to changes in the treatment of brain metastases. In the case of radiotherapy, while whole-brain radiotherapy (WBRT) has been the standard treatment of brain metastases, stereotactic radiosurgery (SRS) is now increasingly preferred to avoid cognitive dysfunction.

Because different tumor types respond differently to these treatments, their clinical course depends on the primary tumor. Thus, brain metastasis is not a single entity; those originating from lung cancers, breast cancers, and colorectal cancers must all be treated differently, but the characteristics and management of brain metastases from each origin have not been clearly elucidated.

As our fundamental understanding of the biology of this disease increases, so does our ability to treat it effectively. This Special Issue will highlight the current management and future prospects for brain metastases and will include the characteristics of brain metastases from the various types of cancer—lung cancer, melanoma, renal cell cancer, breast cancer, colorectal cancer, and so on.

Prof. Dr. Dai Shida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.